Sirankapracha P . Labile plasma iron in iron overload: redox activity and susceptibility to chelation . Blood 2003 ; 102 : 2670 – 2677 . 12. Cortelezzi A Cattaneo C Cristiani S . Non-transferrin-bound iron in myelodysplastic syndromes: a marker
Peter L. Greenberg
Peter L. Greenberg, Cynthia K. Rigsby, Richard M. Stone, H. Joachim Deeg, Steven D. Gore, Michael M. Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Paul J. Shami and Rashmi Kumar
Cristiani S . Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol J 2000 ; 1 : 153 – 158 . 10 Cabantchik ZI Breuer W Zanninelli G Cianciulli P . LPI-labile plasma iron in iron overload
David P. Steensma
through other mechanisms. Reduction of labile plasma iron (LPI), a toxic redox-active form of non–transferrin-bound iron (NTBI) that appears in the plasma when the capacity of plasma transferrin to bind iron released from macrophages and gut epithelium is
Peter L. Greenberg, Eyal Attar, John M. Bennett, Clara D. Bloomfield, Carlos M. De Castro, H. Joachim Deeg, James M. Foran, Karin Gaensler, Guillermo Garcia-Manero, Steven D. Gore, David Head, Rami Komrokji, Lori J. Maness, Michael Millenson, Stephen D. Nimer, Margaret R. O'Donnell, Mark A. Schroeder, Paul J. Shami, Richard M. Stone, James E. Thompson and Peter Westervelt
pathophysiology and adverse effects of chronic iron overload on hepatic, cardiac, and endocrine function. Increased non–transferrin-bound iron levels, generated when plasma iron exceeds transferrin's binding capacity, combines with oxygen to form hydroxyl and
